Maxime Dely on The vital Role of Plasma in Immune-Deficient Patients
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared on LinkedIn:
”Immunoglobulins: when plasma becomes a vital treatment for immune-deficient patients
Intravenous and subcutaneous immunoglobulins (IVIg, SCIg), produced exclusively from plasma donations, are life-saving medicines.
They replace or support the immune system in a wide range of conditions.
Main indications
- Primary immunodeficiencies (rare and severe congenital disorders)
- Secondary immunodeficiencies (after transplantation, chemotherapy, uncontrolled HIV, etc.)
- Autoimmune and neurological diseases (Guillain-Barré syndrome, myasthenia gravis, Kawasaki disease, immune thrombocytopenia, and more)
Worldwide
Today, millions of patients rely on immunoglobulin therapy every year.
Currently, the global demand is growing steadily (+5–7% annually), driven by broader indications and aging populations.
Unfortunately, there is no synthetic or recombinant alternative today — plasma is the only source.
Immunoglobulins are not only life-saving but also critical for maintaining quality of life in chronic patients.
Behind every infusion of immunoglobulins, there are thousands of plasma donations, transformed into precious medicines.
How can we raise more awareness about the growing importance of plasma-derived immunoglobulins, as global demand keeps rising?”
Stay updated on all scientific advances in the field of transfusion medicine with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals